 I. To determine the safety and potential toxicities associated with infusing donor CD8 cytotoxic T lymphocyte CTL clones specific for Wilms tumor WT1 in patients who have relapsed or at a high risk of relapse post transplant for myelodysplastic syndromes MDS, chronic myelogenous leukemia CML, acute myeloid leukemia AML, or acute lymphoblastic leukemia ALL. 